For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Secretagogue Peptide
CJC-1295 / Ipamorelin (No DAC)
A research blend pairing a GHRH analog with the ghrelin-receptor agonist ipamorelin, used to study synchronized growth-hormone release in experimental models.
Size
Quantity
$59.99
Bundle & save
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2 business days
Overnight shipping available
Free shipment protection included
CJC-1295 / Ipamorelin (No DAC)
1 × 10mg · $59.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
| Tested | Measured |
|---|---|
| Jul 2026 | CJC-1295 5.57mg · Ipamorelin 5.88mg |
| Jun 2026 | CJC-1295 5.00mg · Ipamorelin 5.54mg |
| Jun 2026 | CJC-1295 5.64mg · Ipamorelin 5.81mg |
| May 2026 | CJC-1295 5.86mg · Ipamorelin 5.76mg |
| May 2026 | CJC-1295 5.68mg · Ipamorelin 5.62mg |
| Mar 2026 | CJC-1295 5.68mg · Ipamorelin 5.89mg |
| Mar 2026 | CJC-1295 6.61mg · Ipamorelin 6.04mg |
| Feb 2026 | CJC-1295 6.36mg · Ipamorelin 5.67mg |
| Jan 2026 | CJC-1295 6.19mg · Ipamorelin 4.86mg |
| Dec 2025 | CJC-1295 6.33mg · Ipamorelin 5.20mg |
20mg
| Tested | Measured |
|---|---|
| Jul 2026 | CJC-1295 11.22mg · Ipamorelin 11.99mg |
| Jun 2026 | CJC-1295 11.25mg · Ipamorelin 11.60mg |
| May 2026 | CJC-1295 11.65mg · Ipamorelin 11.74mg |
| Apr 2026 | CJC-1295 10.85mg · Ipamorelin 10.56mg |
| Feb 2026 | CJC-1295 12.97mg · Ipamorelin 10.72mg |
| Dec 2025 | CJC-1295 12.96mg · Ipamorelin 10.54mg |
Frequently researched together
Commonly studied alongside CJC-1295 / Ipamorelin (No DAC).
Compound information
Technical specifications
Molecular profile
| Type | GHRH analog |
| Molecular weight | ~3,367 g/mol |
| Amino acids | 29 |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Journal of Clinical Endocrinology & Metabolism
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
2006·DOI: 10.1210/jc.2005-1536·PMID: 16352683Teichman SL, Neale A, Lawrence B et al.
View source - European Journal of Endocrinology
Ipamorelin, the first selective growth hormone secretagogue
1998·DOI: 10.1530/eje.0.1390552·PMID: 9849822Raun K, Hansen BS, Johansen NL et al.
View source - Endocrinology
On the actions of the growth hormone-releasing hexapeptide, GHRP
1991·PMID: 2004615Bowers CY, Reynolds GA, Durham D et al.
View source - Sexual Medicine Reviews
The Safety and Efficacy of Growth Hormone Secretagogues
2018·DOI: 10.1016/j.sxmr.2017.02.004·PMID: 28400207Sigalos JT, Pastuszak AW
View source - Endocrine
Effects of growth hormone and its secretagogues on bone
2001·PMID: 11322502Svensson J, Ohlsson C, Jansson JO et al.
View source - American Journal of Physiology-Endocrinology and Metabolism
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
2006·DOI: 10.1152/ajpendo.00201.2006·PMID: 16822960Alba M, Fintini D, Sagazio A et al.
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.